scispace - formally typeset
H

Harold S. Nelson

Researcher at National Jewish Health

Publications -  52
Citations -  3160

Harold S. Nelson is an academic researcher from National Jewish Health. The author has contributed to research in topics: Asthma & Allergy. The author has an hindex of 24, co-authored 52 publications receiving 3068 citations. Previous affiliations of Harold S. Nelson include University of Genoa & Anschutz Medical Campus.

Papers
More filters
Journal ArticleDOI

Treatment of peanut allergy with rush immunotherapy

TL;DR: Preliminary data demonstrating the efficacy of injection therapy with peanut extract is provided and provides a future line of clinical investigation for the treatment of this potentially lethal disease.
Journal ArticleDOI

Onset and Persistence of Childhood Asthma: Predictors From Infancy

TL;DR: 3 proved to have significant univariate relationships with asthma between ages 6 and 8: elevated IgE levels measured when the children were 6 months of age, global ratings of parenting difficulties measured when infants were 3 weeks old, and higher numbers of respiratory infections in the first year of life.
Journal ArticleDOI

Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009

TL;DR: The Canonica Co-Chairs as discussed by the authors, the first edition of the Canonica International Journal of Distributed Sensoriotemporal Programming (CISDP) conference, were: G. Walter Canonica co-chairs Jean Bousquet, Thomas Casale, Richard F. Lockey, Carlos E. Baena-Cagnani, Ruby Pawankar, Paul C. Ryan, Jan L. Brozek, Enrico Compalati, Ronald Dahl, Luis Delgado, Roy Gerth van Wijk, Richard G. Gower, Dennis K
Journal ArticleDOI

Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.

TL;DR: Daclizumab improved pulmonary function and asthma control in patients with moderate to severe chronic asthma inadequately controlled on ICS, and the mechanism of action likely involves inhibition of proinflammatory cytokine generation by IL-2R blockade in activated T cells.